Revuforj access in India: the CDSCO named-patient pathway
How India patients legally obtain Revuforj (revumenib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Ask about Revuforj in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Revuforj (revumenib) is menin-MLL (KMT2A) interaction inhibitor (oral) approved by the US FDA in November 2024 (accelerated approval) for relapsed or refractory acute leukaemia with a KMT2A translocation in adult and paediatric patients 1 year of age and older. The drug is manufactured by Syndax Pharmaceuticals. India patients use the Central Drugs Standard Control Organization named-patient pathway when the locally registered indication, the stocked presentation, or the available payer coverage does not match what the prescribing physician has written. Reserve Meds coordinates supply through a US-licensed pharmaceutical wholesale partner, builds the documentation packet your physician needs to file, and orchestrates the logistics into India with a single point of contact carrying the case end-to-end.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
Why Indian patients need Revuforj through the named-patient pathway
India operates a developed pharmaceutical regulatory environment, and Revuforj may be on the local register, may be in commercial review, or may be entirely absent depending on the stage of Syndax Pharmaceuticals's regional rollout. Several patterns drive cross-border requests. We give you a written timeline estimate for your case before you commit. Second, biomarker-defined eligibility: KMT2A (MLL) gene rearrangement by FISH or cytogenetics; ideally confirmed by reference-laboratory NGS can be the diagnostic gate, and where the relevant testing infrastructure is still maturing locally, families coordinate the workup before or in parallel with sourcing. Third, payer coverage: private insurers assess specialty therapies case by case, and step-therapy criteria can fail even where the drug is registered. Fourth, stocking gaps: the local agent may not carry every presentation or dose strength reliably, and named-patient import is the operational mechanism that bridges to the exact label the prescriber has written. In each pattern, the named-patient pathway is the legal mechanism that connects an Indian-licensed physician's clinical decision with US-sourced, FDA-labelled product for a specific identified patient.
The CDSCO named-patient pathway for Revuforj
India's personal-import pathway sits under Rule 36 of the New Drugs and Clinical Trials Rules 2019 read with the Drugs and Cosmetics Act 1940. The CDSCO accepts applications via the SUGAM portal at cdscoonline.gov.in for a specific patient where the medicine is approved by a recognised reference authority and a locally registered equivalent is unavailable or unsuitable. Form 12A (institutional Compassionate Use) is the parallel route through a tertiary hospital ethics committee. The framework permits hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and either a clinically equivalent locally registered alternative is not suitable, or the patient's clinical profile does not match the locally approved label.
A complete application for Revuforj typically includes a clinical justification letter from the treating physician documenting the patient's diagnosis (KMT2A-rearranged acute leukaemia), severity assessment, prior systemic therapy history, any relevant biomarker results (KMT2A (MLL) gene rearrangement by FISH or cytogenetics; ideally confirmed by reference-laboratory NGS), and a clinical rationale for selecting Revuforj over locally available alternatives. The Indian physician's licensure with the National Medical Commission and the relevant State Medical Council is verified through the application. The packet also specifies the dispensing facility name and license number, the pharmacy in charge of the facility, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity, intended treatment duration), and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy.
For Revuforj specifically, the clinical justification typically frames the case around Revuforj is the first menin inhibitor approved for KMT2A-rearranged leukaemia (an aggressive subtype with historically poor outcomes); paediatric and adult haematology referral with KMT2A confirmation through reference-lab cytogenetics and NGS anchors the case. We give you a written timeline estimate for your case before you commit. The CDSCO retains discretion on timing, and we do not promise specific durations.
Where Revuforj gets dispensed in India
A focused group of India institutions handle named-patient specialty-medicine imports as established workflow, with in-house import pharmacy capabilities and physicians experienced with the application set. For Revuforj specifically, the dispensing facility must accommodate the administration profile: tertiary haematology or paediatric oncology centre with differentiation-syndrome readiness and ECG monitoring infrastructure; oral self-administered at home between clinic visits.
For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a licensed pharmaceutical establishment that holds the import licence and files the CDSCO application on the prescribing physician's behalf. The medicine then moves under chain-of-custody documentation into the prescribing hospital's outpatient pharmacy for administration.
Real cost picture for Revuforj in India
Medicine price: quote on request. You get a written quote for your case before you commit. The total includes the drug cost, logistics, the CDSCO permit fees, the destination dispensing hospital's administration fees, and Reserve Meds' coordination fee (which is itemised separately on every firm quote).
Medicine price: quote on request. Every case gets a written custom quote before you commit. On the insurance side, private insurers assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation with documented step-therapy failure. We do not promise coverage from any payer. US manufacturer patient assistance programmes do not extend internationally; cross-border patients pay cash or rely on local payer coverage where available.
Clinical evidence and where Revuforj sits in the treatment landscape
AUGMENT-101 (NCT04065399) phase 1/2 trial demonstrated complete response or complete response with partial haematological recovery in 23 percent of heavily pre-treated KMT2A-rearranged acute leukaemia. The drug acts as menin-MLL (KMT2A) interaction inhibitor (oral), and the dosing schedule is weight-banded oral twice daily with food; dose differs by concomitant strong CYP3A4 inhibitor use.
Within the treatment landscape, Revuforj sits alongside high-dose chemotherapy regimens for relapsed acute leukaemia, allogeneic haematopoietic stem cell transplantation (the only curative option for KMT2A-rearranged disease in many cases), the FLT3 inhibitors (gilteritinib, quizartinib) in FLT3-comutated cases, the BCL2 inhibitor venetoclax in combinations, and the related menin inhibitor ziftomenib (in development). The choice between targeted therapies in this space depends on the patient's full clinical profile, prior therapy exposure, biomarker status, comorbidities, and the prescriber's judgment. Reserve Meds coordinates whichever therapy the physician has selected; we do not steer prescribing.
Safety surveillance for Revuforj centres on differentiation syndrome (treatment-emergent, similar to IDH or FLT3 inhibitor experience; corticosteroid management protocols established), QT prolongation (baseline and periodic ECG monitoring with magnesium and potassium repletion), febrile neutropenia, and infections. The dispensing facility and the prescribing physician retain clinical responsibility for monitoring and adverse-event management; Reserve Meds does not provide medical care.
Typical timeline for Revuforj in India
We give you a written timeline estimate for your case before you commit. Where the administration setting is tertiary haematology or paediatric oncology centre with differentiation-syndrome readiness and ECG monitoring infrastructure, hospital scheduling and infusion-chair availability are additional sequencing factors that families plan around. We do not promise specific durations; the CDSCO retains discretion on timing, and shipping windows depend on lane and packaging.
What your Indian physician needs to provide
For an Indian-licensed specialist prescribing Revuforj through the CDSCO pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's diagnosis (KMT2A-rearranged acute leukaemia), the relevant biomarker work (KMT2A (MLL) gene rearrangement by FISH or cytogenetics; ideally confirmed by reference-laboratory NGS), prior systemic therapy history, the FDA-approved indication being invoked, and the clinical rationale for Revuforj as the appropriate next step.
The letter also specifies the exact dosing plan per the FDA-approved label: weight-banded oral twice daily with food; dose differs by concomitant strong CYP3A4 inhibitor use. The monitoring plan references differentiation syndrome (treatment-emergent, similar to IDH or FLT3 inhibitor experience; corticosteroid management protocols established), QT prolongation (baseline and periodic ECG monitoring with magnesium and potassium repletion), febrile neutropenia, and infections. The treating physician's licence number with the National Medical Commission and the relevant State Medical Council, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. Where biomarker testing requires reference-lab coordination, the physician documents the assay used and the report; Reserve Meds can route this through a US-side reference laboratory where the regional pathway is unavailable.
Common questions about Revuforj in India
Will a private insurer cover Revuforj? Each insurer assesses named-patient imports case by case. Some reimburse fully when Revuforj is on their formulary even if not currently stocked; others assess based on step-therapy criteria and biomarker documentation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you, your physician, or your hospital. We do not promise coverage from any payer.
Is Revuforj registered locally in India? Local registration status changes as Syndax Pharmaceuticals pursues regional rollout; even where the drug is registered, the specific indication, presentation, or dosing strength your prescriber has written may not align with what is currently stocked. The CDSCO named-patient pathway exists precisely to bridge these gaps for individually identified patients.
What about competitor therapies? The treatment landscape includes high-dose chemotherapy regimens for relapsed acute leukaemia, allogeneic haematopoietic stem cell transplantation (the only curative option for KMT2A-rearranged disease in many cases), the FLT3 inhibitors (gilteritinib, quizartinib) in FLT3-comutated cases, the BCL2 inhibitor venetoclax in combinations, and the related menin inhibitor ziftomenib (in development). The choice depends on the patient's full clinical profile and prescriber judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not steer prescribing decisions and we do not have a financial relationship with any specific manufacturer.
How is the cold chain or storage managed? Revuforj ships in validated packaging with continuous temperature logging through the lane where cold-chain handling applies. The handoff ends at the dispensing pharmacy; home storage instructions, where the patient takes the medicine home for self-administration, are part of the patient onboarding kit.
Do US manufacturer patient assistance programmes (such as Syndax Pharmaceuticals co-pay or PAP programmes) extend to India patients? No. US-resident patient assistance programmes are limited to US-resident patients with US prescription coverage by programme design. Cross-border patients pay cash for the drug and the coordination fee, with local payer reimbursement assessed separately.
Can the case be resupplied year over year if the patient responds? Yes. Reserve Meds maintains the case file and re-files CDSCO permits at the relevant intervals (or coordinates with the dispensing hospital's pharmacy if they hold the permit). Patients on long-term therapy typically settle into a quarterly or biannual resupply cadence after the first cycle.
What is the administration setting? Tertiary haematology or paediatric oncology centre with differentiation-syndrome readiness and ecg monitoring infrastructure; oral self-administered at home between clinic visits.
My physician is at a smaller hospital without an internal import pharmacy. Can the case still proceed? Yes. The common pattern is to route through a Dubai, Riyadh, Mumbai, Cairo, Karachi, or other regional licensed pharmaceutical establishment that holds the import licence and files the CDSCO application on the prescribing physician's behalf. The medicine moves into the prescribing hospital's outpatient pharmacy under chain-of-custody documentation.
Where Reserve Meds fits in Revuforj cases
Reserve Meds is a US-based digital health company. We do not replace your Indian specialist, we do not replace the CDSCO, and we do not replace your dispensing pharmacy. For Revuforj specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate logistics into India, and give you one point of contact through the case. The pharmacist-of-record review, prescription validation, biomarker confirmation, and physician sign-off are the recurring operational fundamentals for this drug.
Next step
If your Indian physician has prescribed Revuforj and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.